La cadena de opciones muestra datos clave de las opciones de acciones de Ontrak a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Ontrak..

Ontrak (NASDAQ:OTRK) Bolsa, Cadena de Opciones

Ontrak

Ontrak Inc is an artificial intelligence (AI)-powered and technology-enabled behavioral healthcare company, whose mission is to help improve the health and save the lives of as many people as possible. The Company's technology-enabled platform utilizes claim-based analytics and predictive modeling to provide analytic insights throughout the delivery of our personalized care program. The company's integrated, technology-enabled OntrakTM solutions, a component of the PRE platform, are designed to treat members with behavioral conditions that cause chronic medical conditions such as diabetes, hypertension, coronary artery disease, COPD, and congestive heart failure.

Ontrak Inc

Piper Sandler analyst Derek Podhaizer assumes Atlas Energy Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AESI#NYSE">AESI</a>) with a Overweight rating and announces Price Target of $22.

News

Price Target

Initiation

Analyst Ratings

AESI

Piper Sandler Assumes Atlas Energy Solutions at Overweight, Announces Price Target of $22

HC Wainwright &amp; Co. analyst Sean Lee maintains Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) with a Buy and raises the price target from $7.5 to $9.5.

HC Wainwright & Co. Maintains Buy on Myomo, Raises Price Target to $9.5

TRNR

Interactive Strength Inc.  Secures $3.6M in 3-Year Notes From Institutional Investor, Following $2.9M Investment

Earnings

VNET

VNET Q4 EPADS $(0.01) Misses $0.03 Estimate, Sales $307.75M Beat $284.88M Estimate

For the full-year 2025, which will set the stage to become a pure-play Power company, we currently expect:
<ul>
<li>Consolidated revenue from continuing operations to grow mid-to-high single digit year-over-year as compared with equivalent revenue of $185.8 million in 2024.</li>
<li>Consolidated gross profit margin from continuing operations between 19.5% to 21.5%, reflecting the fact that we have completed the wind down of Transitional Foundry Services and new generation power products will just begin production in the second half 2025. The equivalent gross profit margin was 21.5% in 2024.</li>
</ul>

Guidance

Magnachip Expects FY25 Revenue Growth From Continuing Operations Of Mid-To-High Single Digit Vs $185.8M YoY

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) with a Buy and maintains $40 price target.

Reiteration

DNTH

HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $40 Price Target

TSLA CLIMBS OVER 14 POINTS AFTER ALERT
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/11205022/Screenshot-2025-03-11-at-4.48.04%E2%80%AFPM-1021x1024.png" alt="" class="wp-image-7659" /></figure>
Tesla, Inc. (TSLA) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 09:46 AM on March 11th, a significant trading signal occurred for Tesla, Inc. (TSLA) as it demonstrated a Power Inflow at a price of $222.68. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Tesla&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Tesla&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for TSLA, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts. 
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; &nbsp; <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>&nbsp; which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $222.68. The returns on the High price ($236.94) and Close price ($230.58) after the Power Inflow were respectively 6.4% and 3.5%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. 
Past Performance is Not Indicative of Future Results

Equities

Technicals

Signals

Markets

Trading Ideas

Tesla Stock Pares Early Losses, Rises 6.4% After Key Signal

The company continues to&nbsp;tightly manage its operating expenses and its cash position. The company reaffirms its belief that current cash and investments and other assets are adequate to support continuing operations for the foreseeable future.

AMRN

Amarin Says Continuing To Explore All Strategies To Accelerate Growth In Europe Region

KalVista Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.87) by 5.75 percent. This is a 9.52 percent decrease over losses of $(0.84) per share from the same period last year.

KALV

KalVista Pharma Q3 2025 GAAP EPS $(0.92) Misses $(0.87) Estimate, The Company Had Cash, Cash Equivalents And Marketable Securities Of Approximately $253.2M

WIIM

VSTE

Vast Renewables shares are trading higher after the company received up to AUD180M in conditional funding from the Australian Renewable Energy Agency for its Port Augusta clean energy project.

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Endeavour Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXK#NYSE">EXK</a>) with a Buy and raises the price target from $7 to $7.25.

HC Wainwright & Co. Maintains Buy on Endeavour Silver, Raises Price Target to $7.25

For Q1 2025:
<ul>
<li>Consolidated revenue from continuing operations (which includes Power discrete and Power IC businesses, and excludes our former Display business) to be in the range of $42 to $47 million, down 8.9% sequentially due primarily to seasonality, but up 11.5% year-over-year at the mid-point. This compares with equivalent revenue of $48.9 million in Q4 2024 and $39.9 million in Q1 2024.</li>
<li>Consolidated gross profit margin from continuing operations to be in the range of 18.5% to 20.5%, due to the seasonal sequential decline in revenue and the wind down of Transitional Foundry Services impacting fab utilization. This compares with equivalent gross profit margin of 23.2% in Q4 2024 and 17.6% in Q1 2024.</li>
</ul>

Magnachip Expects Q1 Revenue From Continuing Operations Of $42M-$47M, Up 11.5% YoY

Financing

Vast Renewables Limited Receives Up To AUD180M Of Conditional Funding From Australian Renewable Energy Agency For Construction Of Its Port Augusta Utility-Scale Clean Energy Project

Full-Year 2025 Guidance
In 2025, the Company expects to generate Adjusted EBITDA between $1.6 billion and $2.2 billion and Adjusted EBIT between $350 million and $950 million.

ZIM Integrated Shipping Services 2025 Outlook: Expects Adjusted EBITDA Of $1.6B-$2.2B And Adjusted EBIT Of $350M-$950M

Amarin Intends To Effect Ratio Change On ADSs From One ADS Representing One Ordinary Share To New Ratio Of One ADS Representing 20 Ordinary Shares

HC Wainwright &amp; Co. analyst Scott Buck reiterates Redwire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) with a Buy and maintains $26 price target.

HC Wainwright & Co. Reiterates Buy on Redwire, Maintains $26 Price Target

Stock Split

Amarin To Effect An ADS Ratio Change From One ADS Representing One Ordinary Share To One ADS Representing Twenty Ordinary Shares

Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.11 by 72.73 percent. This is a 76.92 percent decrease over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $143.537 million which missed the analyst consensus estimate of $162.060 million by 11.43 percent. This is a 13.18 percent decrease over sales of $165.318 million the same period last year.

Earnings Misses

Solo Brands Q4 2024 Adj. EPS $0.03 Misses $0.11 Estimate, Sales $143.537M Miss $162.060M Estimate

InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 18.75 percent decrease over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $1.95 million which beat the analyst consensus estimate of $1.82 million by 7.29 percent. This is a 10.68 percent increase over sales of $1.76 million the same period last year.

NSPR

InspireMD Q4 2024 GAAP EPS $(0.19) Beats $(0.20) Estimate, Sales $1.95M Beat $1.82M Estimate

Earnings Beats

HBIO

Harvard Bioscience Q4 2024 Adj. EPS $0.06 Beats $0.05 Estimate, Sales $24.556M Beat $24.150M Estimate

Press Releases

Ontrak Health Demonstrates Significant Improvement in Members' Quality of Life from ReQoL Mental Health Assessment

Ontrak, Inc. Announces Reverse Stock Split

"Peraso Inc. (NASDAQ: PSRO) Pioneers mmWave Technology: The Next-Generation Wireless Communications" see bonus stocks inside…..

Ontrak Health Collaborates with Major Northeast Regional Plan to Bridge HEDIS Care Gaps Using Ontrak Quality Solution

Ontrak Health to Report 2024 Third Quarter Financial Results on November 13, 2024

Ontrak Health Expands Behavioral Health Solutions with Sentara Health Plans for Commercial and Marketplace Populations

Ontrak Health Announces 2024 Third Quarter Financial Results

Ontrak Health Announces New Customer Partnership with Intermountain Health to Deliver Value-Based Behavioral Health Services to Medicare Advantage Members

Ontrak Health and Sentara Health Plans Execute Three-year Contract Extension Following Several Expansions

Ontrak Health Announces Launch of WholeHealth+ Solution for Intermountain Health

BPTH

LASE

OTRK

PSRO

American Shared Hospital Services Common Stock

American Shared Hospital

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Kindly MD

23andMe Holding

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

ModivCare

MSP Recovery, Inc. - Class A Common Stock

MSP Recovery

NewGenIvf Group Limited - Class A Ordinary Shares

NewGenIvf Group

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

Precipio

SHL Telemedicine Ltd - American Depositary Shares

Comments

Ontrak

Ontrak (OTRK) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL